Efficacy and Safety of Naproxcinod in Patients with Osteoarthritis of the Knee: A 53-Week Prospective Randomized Multicenter Study

Naproxcinod 750 mg bid and 375 mg bid demonstrated superior efficacy over placebo for treatment of OA and were well tolerated over 1 year. Naproxcinod 750 mg bid was noninferior to naproxen 500 mg bid.